ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Returning to our K562 CRISPRi/a models, which are patient-derivedBCR-ABL1 mutant CML cells, we characterized the effect of IFITM expression onthe ability of DasatiLink-1 to inhibit intracellular BCR-ABL1 signaling.